Prognostic value of phospho-Akt in patients with non-small cell lung carcinoma: A meta-analysis

International Journal of Cancer

Volumn 135, Issue 6, 2014, Pages 1417-1424

  Yang, Yang ^a,b   Luo, Jialin ^a,b   Zhai, Xiaoming ^c   Fu, Zhiqin ^a   Tang, Zhongzhu ^a,b   Liu, Luying ^a,b   Chen, Ming ^a,b   Zhu, Yuan ^a,b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Zhejiang Province Key Laboratory of Biofuel   (China)

^c The First Affiliated Hospital   (China)

Author keywords

lung cancer; meta analysis; p Akt; prognostic factor; survival

Indexed keywords

PROTEIN KINASE B;

ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DATA ANALYSIS; DISEASE ASSOCIATION; ENZYME ASSAY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME;

LUNG CANCER; META-ANALYSIS; P-AKT; PROGNOSTIC FACTOR; SURVIVAL;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROGNOSIS;

EID: 84904060626     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28788     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-41.
3. Coate LE, John T, Tsao MS, et al. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009; 10: 1001-10.
4. Brazil DP, Park J, Hemmings BA,. PKB binding proteins: getting in on the akt. Cell 2002; 111: 293-303.
5. Manning BD, Cantley LC,. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-74.
6. Nicholson KM, Anderson NG,. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-95.
7. Massion PP, Taflan PM, Shyr Y, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Resp Crit Care 2004; 170: 1088-94.
8. Steelman LS, Stadelman KM, Chappell WH, et al. Akt as a therapeutic target in cancer. Expert Opin Ther Tar 2008; 12: 1139-65.
9. Perez-Tenorio G, Stal O, Group SSBC,. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002; 86: 540-5.
10. Dai DL, Martinka M, Li G,. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 2005; 23: 1473-82.
11. Massarelli E, Liu DD, Lee JJ, et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer 2005; 104: 2430-6.
12. Yoshioka A, Miyata H, Doki Y, et al. The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. Oncol Rep 2008; 19: 1099-107.
13. Hager M, Haufe H, Kemmerling R, et al. Increased activated Akt expression in renal cell carcinomas and prognosis. J Cell Mol Med 2009; 13: 2181-8.
14. Guo RX, Qiao YH, Zhou Y, et al. Increased staining for phosphorylated AKT and nuclear factor-kappa B p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int 2008; 58: 749-56.
15. David O, Jett J, LeBeau H, et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004; 10: 6865-71.
16. Lim WT, Zhang WH, Miller CR, et al. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep 2007; 17: 853-7.
17. Tang JM, He QY, Guo RX, et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer J Iaslc 2006; 51: 181-91.
18. Ikeda S, Takabe K, Inagaki M, et al. Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas. Pathol Int 2007; 57: 268-75.
19. Al-Saad S, Donnem T, Al-Shibli K, et al. Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res 2009; 29: 4175-83.
20. Yoshizawa A, Fukuoka J, Shimizu S, et al. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 2010; 16: 240-8.
21. Milella M, Nuzzo C, Bria E, et al. EGFR molecular profiling in advanced NSCLC a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. J Thorac Oncol 2012; 7: 672-80.
22. Hirami Y, Aoe M, Tsukuda K, et al. Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-1 alpha in non-small cell lung cancers. Cancer Lett 2004; 214: 157-64.
23. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer I 2004; 96: 1133-41.
24. Tsurutani J, Fukuoka J, Tsurutani H, et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 2006; 24: 306-14.
25. Okamura M, Yamaji S, Nagashima Y, et al. Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol 2007; 38: 1081-91.
26. Zuli Zhou FY, Jiang G, Huang Y, et al. Phophorylated Akt protein expression in non-small cell lung cancer Chinese J Lung Cancer 2007; 10: 5.
27. Tsurutani J, Steinberg SM, Ballas M, et al. Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer J Iaslc 2007; 55: 115-21.
28. Schneider CP, Heigener D, Schott-von-Romer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J Thorac Oncol 2008; 3: 1446-53.
29. Hosokawa S, Toyooka S, Fujiwara Y, et al. Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer J Iaslc 2009; 66: 107-13.
30. Liu D, Huang Y, Chen B, et al. Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Cancer 2011; 117: 3763-73.
31. Shah A, Swain WA, Richardson D, et al. Phospho-Akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 2930-6.
32. Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005; 113: 109-15.
33. Steels E, Paesmans B, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001; 18: 705-19.
34. Parmar MK, Torri V, Stewart L,. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-34.
35. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007: 16 http://www.trialsjournal.com/content/8/1/16; 8.
36. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
37. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 11.
38. Tobias A,. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 1999; 8: 12.
39. Sterne JAC, Egger M,. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-55.
40. West KA, Brognard J, Clark AS, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003; 111: 81-90.
41. Brognard J, Clark AS, Ni YC, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-97.
42. Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956-67.
43. Schuurbiers OCJ, Kaanders JHAM, van der Heijden HFM, et al. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 2009; 4: 761-7.
44. Li TH, Kung HJ, Mack PC, et al. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013; 31: 1039-49.
45. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer I 2005; 97: 643-55.
46. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-501.
47. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-7.
48. Altomare DA, Testa JR,. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-64.